Recent articles for private investors with a focus on dividend announcements
Alent 2015 interim results
Growth in NSV of 1.9% on a reported basis (0.5% on a constant currency basis), reflecting end-market headwinds
Lloyds Banking group pays 0.75p 2015 interim dividend
Improvement in underlying and statutory profit with balance sheet further strengthened
BG Group 2015 Interim results
E&P production up 19% at 703 kboed; full year guidance moved to the upper half of 650 - 690 kboed range
Laird increases its 2015 interim dividend by 3%
Good first half performance in line with expectations
Countrywide maintains its 2015 interim dividend at last years level
Group income grew to £338.6 million, however, a difficult UK housing market led to £41.0 million of EBITDA versus £45.0 million in the same period last year
Millenium and Copthorn maintains its 2015 interim dividend
Group RevPAR grew by 4.0% to £68.28. In constant currency, RevPAR increased by 0.8% from £67.75 to £68.28. Average room rate increased by 2.7% to £96.61 (H1 2014: £94.10) and occupancy fell by 1.2 percentage points to 70.7% (H1 2014: 71.9%).
Astra Zeneca maintains its 2015 interim dividend at $0.90
Total H1 Revenue up 1%; Core Gross margin over 83%, up 1% point
INTU maintains its 2015 interim dividend
The Directors of Intu Properties plc have announced an interim dividend per ordinary share (ISIN GB0006834344) of 4.6 pence (2014 - 4.6 pence) payable on 24 November 2015 (see salient dates below). A scrip dividend alternative will continue to be offered.
The dividend may be partly paid as a Property Income Distribution ("PID") and partly paid as a non-PID. The PID element will be subject to deduction of a 20 per cent withholding tax unless exemptions apply (please refer to the PID special note below). Any non-PID element will be treated as an ordinary UK company dividend. For South African shareholders, any non-PID cash dividends may be subject to deduction of South African Dividends Tax at 15 per cent.
Shareholders will be advised of the PID/non-PID split no later than Friday 2 October 2015.
Dates
The following are the salient dates for the payment of the interim dividend:
Thursday, 8 October 2015
Sterling/Rand exchange rate struck.
Friday, 9 October 2015
Sterling/Rand exchange rate and dividend amount in SA currency announced.
Monday, 19 October 2015
Ordinary shares listed ex-dividend on the JSE, Johannesburg
Thursday, 22 October 2015
Ordinary shares listed ex-dividend on the London Stock Exchange.
Friday, 23 October 2015
Record date for interim dividend in London and Johannesburg.
Friday, 30 October 2015
UK shareholders only: Last date for receipt of Tax Exemption Declaration forms to permit dividends to be paid gross.
Tuesday, 24 November 2015
Dividend payment day for shareholders
South African shareholders should note that, in accordance with the requirements of Strate, the last day to trade cum-dividend will be Friday, 16 October 2015 and that no dematerialisation or rematerialisation of shares will be possible from Monday, 19 October to Friday, 23 October 2015 inclusive. No transfers between the UK and South African registers may take place from Wednesday, 7 October to Sunday, 25 October 2015 inclusive.
Hendersons increases its 2015 interim dividend by 19.2%
Henderson Group plc (Henderson or the Group) published its Interim Results for the six months ended 30 June 2015 on 30 July 2015. The comments below refer to the period from 1 January to 30 June 2015 (the period) unless otherwise stated.
Foreign & Colonial investment trust 2015 interim results
SUMMARY OF UNAUDITED RESULTS FOR THE HALF-YEAR ENDED 30 JUNE 2015
Weir group holds its 2015 interim dividend at last years level
Dividend The Board has decided to hold the interim dividend flat at 15.0p (2014: 15.0p). The interim dividend will be paid on 6 November 2015 to shareholders on the register on 9 October 2015.
Rolls Royce increases its 2015 interim 'payment to shareholders' by 3%
Warren East, Chief Executive, said: "Despite the disappointment of our recent update, our second half outlook remains positive and full-year guidance for revenue, profit and cash issued on July 6th remains unchanged. The continued growth in our order book demonstrates the long-term demand for our innovative products and services, and underpins my confidence in the fundamental strength of our business."
Schroders increases its 2015 interim dividend by 21%
Profit before tax and exceptional items up 17 per cent. to £305.7 million (H1 2014: £261.5 million)
Money supermarket increses its 2015 interim dividend by 10%
Insurance revenues up 8% with car insurance premiums starting to show a marginal increase.
Royal Dutch Shell 2015 interim results
Royal Dutch Shell’s second quarter 2015 earnings, on a current cost of supplies (CCS) basis (see Note 2), were $3.4 billion compared with $5.1 billion for the same quarter a year ago.
Law debenture Group 2015 interim results
HALF YEARLY REPORT FOR THE SIX MONTHS TO 30 JUNE 2015 (unaudited)
Capital and Counties 2015 interim results
Highlights Driving value creation through a clear and focused strategy
GlaxoSmithKline 2015 Q2 results
Summary
·
Group sales +7% CER on a reported basis and +2% CER pro-forma
-
Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma)
-
New Pharmaceutical and Vaccine sales of £446 million in Q2
·
Q2 core EPS of 17.3p, flat in CER terms
-
EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions
-
Integration of new Consumer and Vaccine businesses on track
-
On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes
·
Total Q2 EPS of 3.1p and H1 EPS of 170.7p
-
Reflects phasing of pre-tax transaction gains and accelerated restructuring charges
·
2015 earnings guidance and 2016 outlook reiterated
-
Expect 2015 core EPS to decline at a high teen percentage rate (CER)
-
2016 core EPS percentage growth expected to reach double digits (CER)
·
Q2 dividend of 19p declared
-
Continued expectation for full year dividend of 80p
·
R&D innovation with significant potential to drive long-term Group performance
-
Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan
-
Positive CHMP decision received for Mosquirix
-
Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases
-
New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
Jupiter fund management increases its 2015 interim dividend by 8.1%
Continued organic flow growth from our core mutual fund franchise, with net mutual fund inflows of £1.4bn
4801-4850 of 7560
